InnoCare Pharma Ltd.SSE: 688428

Announcement on Signing License Agreement for CD20*CD3 Bispecific Antibody (ICP-B02/CM355) between Subsidiary and Prolium

· Issued by InnoCare Pharma Ltd. via Shanghai Stock Exchange

Filed with SSE ·

On 6ix: 6ix.com/news/announcement-on-signing-license-agreement-for-cd20cd3-bispecific-antibody-icp-b02cm355-between-subsidiary-and-prolium

Announcement on Signing License Agreement for CD20*CD3 Bispecific Antibody (ICP-B02/CM355) between Subsidiary and Prolium

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

InnoCare Pharma Ltd. on 6ix

Earlier from InnoCare Pharma

Later from InnoCare Pharma

All InnoCare Pharma news releases